SVRA – savara, inc. (US:NASDAQ)
Stock Stats
News
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings, Inc..
Savara (NASDAQ:SVRA) was given a new $10.00 price target on by analysts at UBS Group AG.
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
Savara (NASDAQ:SVRA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) [Yahoo! Finance]
Form 4 Savara Inc For: Dec 19 Filed by: RAMSAY DAVID A
Form 144 Savara Inc Filed by: RAMSAY DAVID A
Form 4 Savara Inc For: Dec 14 Filed by: Lowrance David L
Form 4 Savara Inc For: Dec 14 Filed by: Pauls Matthew
Form 4 Savara Inc For: Dec 14 Filed by: Lutz Robert Matthew
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.